Bio Medica Laboratories was incorporated on August 14, 2015. The company manufactures pharmaceutical injectable formulations for human and veterinary use, operating on a B2B contract manufacturing model. Its portfolio includes liquid and dry powder injections produced under GMP and GLP-certified facilities equipped with advanced quality testing infrastructure
| Bidding Dates |
|---|
| 21 May 2026 - 25 May 2026 |
| Subscription |
|---|
| 2.19x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹2,64,000 | 2 | 2 | 1000 | 3.8 M | ₹132 - ₹139 | 67.7 % | ₹497.9 M - ₹524.3 M | RHP DOC |
Bio Medica Laboratories IPO SUBSCRIPTION STATUS
25 May '26Bio Medica Laboratories IPO overall subscription rate was 2.19 times the total available shares
Bio Medica Laboratories IPO retail subscription rate was 3.96 times in the retail segment
Bio Medica Laboratories IPO non-institutional investor subscription rate was 4.37 times in the non-institutional investor category
Bio Medica Laboratories IPO Qualified Institutional Bidder subscription rate was 0.3 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
25 May 2026 (Day 3) | 3.96x | 4.37x | 0.3x |
22 May 2026 (Day 2) | 1.92x | 1.19x | 0.3x |
21 May 2026 (Day 1) | 1.48x | 0.09x | 0.3x |
Bio Medica Laboratories FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| 8MFY26 | 28.5 | 8.7 | -5.8 | -6.9 | 47.1% |
| FY25 | 38.2 | 9.8 | -3.7 | -3.7 | 39.8% |
| FY24 | 15.2 | 2.5 | 1.6 | 0.1 | 36.9% |
| FY23 | 1.0 | 0.1 | 0.1 | -1.7 | 10.5% |
Note: FY23, FY24, & FY25 financials are standalone basis
Bio Medica Laboratories IPO SUBSCRIPTION STATUS DETAILS
Bio Medica Laboratories had 3.8 M shares on offer
Bio Medica Laboratories IPO offer price was in the range ₹132 - ₹139
Bio Medica Laboratories IPO minimum Investment was ₹264000
Bio Medica Laboratories IPO issue size was ₹ 497.9 M - ₹ 524.3 M
Bio Medica Laboratories had a minimum lot size of 1000 Shares per application
Bio Medica Laboratories NUMBER OF SHARES ON OFFER
Bio Medica Laboratories IPO IMPORTANT DATES
| Issue Open Date | 21 May 2026 |
| Issue close Date | 25 May 2026 |
| Allotment Date | 26 May 2026 |
| Refund Date | 27 May 2026 |
| Demat Account Credit Date | 27 May 2026 |
| Listing Date | 29 May 2026 |
| Listing on Exchange(s) | NSE |
| Bio Medica Laboratories Allotment Status | Exchange/ Registrar |
Bio Medica Laboratories IPO subscription opened on 21 May 2026, and closed on 25 May 2026
IPO allotment for Bio Medica Laboratories was finalized on Tuesday, 26 May 2026
IPO listing for Bio Medica Laboratories was on NSE on Friday, 29 May 2026
Bio Medica Laboratories IPO LISTING GAINS
| Issue Price (adjusted) | 139.0 |
| Listing Open Price | 111.2 |
| Listing Close Price | 115.8 |
| Listing Gain% | -20.0% |
| Current Gain% | 3.9% |
Bio Medica Laboratories Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | 144.4 | 181.5 | 11.1 | 4.2 | 44.8 | 16.2 | 43.1 | 11.9 | 12.9 | ||||
| Sun Pharmaceutical Industries Ltd. | 1930 | 463071.7 | 38.3 | 2.3 | 7.7 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8477 | 225037.7 | 76.9 | 2.9 | 20 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4833 | 183831.8 | 84.3 | 9.4 | 11.7 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1450 | 117138.7 | 34.8 | -0.9 | 4.1 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1135.2 | 114227.7 | 25.3 | -16.3 | 4 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 44.9 | -1.6 |
Bio Medica Laboratories INFORMATION ON IPO ISSUE
About Bio Medica Laboratories
Bio Medica Laboratories was incorporated on August 14, 2015. The company manufactures pharmaceutical injectable formulations for human and veterinary use, operating on a B2B contract manufacturing model. Its portfolio includes liquid and dry powder injections produced under GMP and GLP-certified facilities equipped with advanced quality testing infrastructure
Object of the Issue
- To meet out the repayment of loan
- Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises
- To meet out the general corporate purposes
Bio Medica Laboratories - PROMOTERS
| Name |
|---|
| Pradeep Mehta |
| Mukesh Mehta |
Bio Medica Laboratories - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Pradeep Mehta | Managing Director |
| Mukesh Mehta | Whole Time Director |
| Surabhi Mahajan | Director |
| Divya Khandelwal | Independent Director |
| Sumeet Bansal | Independent Director |
Bio Medica Laboratories Book Running Lead Manager
Narnolia Financial Services Limited
ipo@narnolia.com
Bio Medica Laboratories Registrar to the issue
Skyline Financial Services Private Limited
ipo@skylinerta.com
Bio Medica Laboratories Strengths
Quality standards
The company follows strict quality assurance processes supported by GLP and GMP certifications. Its in-house quality control team conducts regular testing of raw materials and finished products to ensure compliance with regulatory and quality standards
Diverse portfolio
The company manufactures a wide range of generic drugs, branded pharmaceuticals, and OTC products. Its flexible manufacturing setup supports multiple formulations and helps cater to changing market demands
Employee stability
The company maintains a low employee attrition rate, reflecting workforce stability and retention. Its focus on employee development and career growth supports operational continuity and long-term business growth
Bio Medica Laboratories Risks
Client concentration
The company depends on a limited number of clients for a significant share of revenue. Loss of any key client or unfavorable contract terms could adversely affect business performance and financial results
Regulatory suspension
Operations at one manufacturing unit were suspended due to regulatory non-compliances. Continued restrictions or cancellation of the license could disrupt production, increase operational pressure on other facilities, and impact overall business performance
Transport dependence
The company relies heavily on third-party transport providers for raw material supply and product delivery. Delays, damages, rising freight costs, or transport disruptions could negatively affect operations, customer relationships, and profitability
IPO FAQs
This IPO consists of an offer for sale of up to Rs 5.2 crore, of 377,000 shares. It also consists of a fresh issue of Rs 47.2 crore.
The promoters of the company are Pradeep Mehta and Mukesh Mehta.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 132.0 - 139.0.
The IPO application opens on May 21, 2026 and closes on May 25, 2026.
The minimum lot size for the IPO is 2000. The maximum lot size for the IPO is 2000.
For all category investors, the minimum application amount for this IPO is Rs. 264,000.0, the maximum value for this IPO is Rs 278,000.0.
This IPO will be allotted on May 26, 2026.
The refund will be credited to your account on May 27, 2026.
The allotted shares will be credited to your demat on May 27, 2026.
Bio Medica Laboratories Ltd.’s shares listed on the stock exchanges on May 29, 2026.